fig1
![Therapeutic approach targeting apolipoprotein E binding region and low-density lipoprotein receptor for Alzheimer's disease](https://image.oaes.cc/aa21e462-412d-4bc6-a920-6ec0859c2b32/2714.fig.1.png)
Figure 1. (A) ApoE4 has a 50 fold increased binding affinity to LDL receptor compared to ApoE2 (B). A novel approach is to create a peptide targeting the ApoE LDLR binding domain. This peptide can work as a competitive antagonist for patients who are ApoE4 carriers. Blocking the effect of ApoE4 binding affinity can help create a more ApoE2-like structure. ApoE2 is known to be protective in AD